Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;219(10):e20212397. doi: 10.1084/jem.20212397

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Qiu et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — Topical propionate application ameliorates the symptoms of AD patients. (A) Representative photographs of symmetrical lesions in AD patients at enrollment (week 0) and week 2 after topical propionate or vehicle application. Scale bar = 1 cm. (B–D) Before- and after-treatment scores for skin symptom intensity (B), subjective pruritus (C), and treated region-specific SCORAD (D) of the propionate- or vehicle-treated region as measured by SCORAD protocol (n = 11). Treated region-specific SCORAD score is the sum of skin symptom intensity and pruritus scores. (E and F) Before- and after-treatment levels of TEWL (E) and skin hydration (F) of the propionate- or vehicle-treated region in enrolled AD patients (n = 6). Statistical significance was analyzed using paired t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.